Doctors and scientists at Sloan Kettering Cancer Center strongly object to its for-profit deal with AI startup PAIGE for exclusive rights to patient data
An artificial intelligence start-up founded by three insiders at Memorial Sloan Kettering Cancer Center debuted with great fanfare in February …
Context & Ripple Effects
PAIGE debuted in February 2018 with a $25M Series A built on an unusual asset: exclusive access to Memorial Sloan Kettering's roughly 25 million pathology slides, granted to a company founded by three of the center's own insiders. The Times report now reveals that the institution's own doctors and scientists strongly objected to that arrangement — a rare public split between a medical center's clinical staff and its commercial leadership over who owns patient-derived data.
The objection matters because the deal became the template rather than an outlier: the same slides later underpinned FDA clearance of Paige's prostate cancer detection program, while rivals pursued different structures, such as the Palantir–Merck KGaA Syntropy joint venture selling analytics to research centers.
First-order effects
- MSK faces immediate internal and reputational pressure over granting a founder-affiliated startup exclusive rights to patient data, forcing the center to defend or renegotiate terms its own clinicians reject.
- PAIGE's core asset — exclusivity over one of the largest pathology slide archives — is now publicly contested, raising diligence questions for its investors and future partners.
Second-order effects
- Other hospitals weighing data partnerships now have a cautionary case study, pushing them toward non-exclusive or joint-venture structures like Syntropy instead of single-startup exclusivity.
- Patient-facing scrutiny grows: as STAT reported in 2020, most patients are unaware their care feeds AI decision-support tools, so disputes like this one put consent and disclosure practices on hospital boards' agendas.
Third-order effects
- If clinician objections harden into policy, academic medical centers will need formal governance — ethics review, revenue-sharing, and consent frameworks — before licensing clinical archives, slowing the exclusive-data-deal model that funded PAIGE and later entrants like Manas AI.
- The pattern points toward clinical data becoming a regulated, negotiated asset class rather than an institution's freely licensable property, with physician bodies gaining standing in commercialization decisions.
The trend: Academic medical centers are monetizing clinical data through exclusive AI startup deals, and physician dissent at Sloan Kettering marks the first serious challenge to whether institutions can sign away patient-derived archives without internal consent.